glp-1 microbiome Boost Synergy Probiotic for Gut and Digestive Health GLP‐1 agonists and the gut

Inclusion criteria were studies involving adult patients (18 years) with T2DM and CVD

News provided by Designs for Health Jun 17, 2026, 10:17 ET New probiotic and postbiotic blend targets microbiome health, metabolic balance, and healthy body composition through clinically studied ingredients* PALM COAST, Fla., June 17, 2026 /PRNewswire/ -- Designs for Health, the practitioner-recommended and preferred brand for high-quality, research-backed supplements, today announced the launch of Akkermansia Pro GLP-1 Probiotic, a groundbreaking once-daily probiotic and postbiotic formula that combines live Akkermansia muciniphila with the clinically studied BPL1 postbiotic to support the gutmetabolic connection, the body's natural GLP-1 production, and healthy weight management.* As research continues to explore the connection between the gut microbiome and metabolic health, emerging science suggests that specific keystone bacterial strains, those that are foundational to the gut microbiome, may play a vital role in supporting appetite regulation, blood sugar metabolism, gut barrier integrity, and overall metabolic resilience

More than 90% of GERD complications involved Barrett esophagus, in which acid damage changes the tissue lining of the esophagus and increases cancer risk, researchers noted

It is available as an oral formulation under the brand name Rybelsus and as an injectable medication under the brand name Ozempic

[2] However, findings suggest that the majority of individuals that start a GLP-1 do not take the medication for the recommended 12 weeks, suggesting they are not achieving clinically meaningful weight loss.[2] Currently, 1 in 8 American adults have used one of the GLP-1 drugs and at least 30% ceased before 4 weeks, likely due to gastrointestinal distress.[2] Additionally, it is reported that there were over 25,000 emergency room visits between 2022-2023 due to GLP-1 use

Liraglutide attenuates diabetic cardiomyopathy via the ILK/PI3K/AKT/PTEN signaling pathway in rats with streptozotocin-induced type 2 diabetes mellitus